Knight Therapeutics Inc. GUD.TO Stock
Knight Therapeutics Inc. Price Chart
Knight Therapeutics Inc. GUD.TO Financial and Trading Overview
Knight Therapeutics Inc. stock price | 5.7 CAD |
Previous Close | 4.82 CAD |
Open | 4.83 CAD |
Bid | 4.83 CAD x 0 |
Ask | 4.86 CAD x 0 |
Day's Range | 4.82 - 4.86 CAD |
52 Week Range | 4.28 - 6.2 CAD |
Volume | 67.18K CAD |
Avg. Volume | 132.34K CAD |
Market Cap | 526.78M CAD |
Beta (5Y Monthly) | 0.472823 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.16 CAD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 6.15 CAD |
GUD.TO Valuation Measures
Enterprise Value | 431.65M CAD |
Trailing P/E | N/A |
Forward P/E | -80.66667 |
PEG Ratio (5 yr expected) | -1240 |
Price/Sales (ttm) | 1.6864918 |
Price/Book (mrq) | 0.6506251 |
Enterprise Value/Revenue | 1.382 |
Enterprise Value/EBITDA | 9.258 |
Trading Information
Knight Therapeutics Inc. Stock Price History
Beta (5Y Monthly) | 0.472823 |
52-Week Change | -6.019% |
S&P500 52-Week Change | 20.43% |
52 Week High | 6.2 CAD |
52 Week Low | 4.28 CAD |
50-Day Moving Average | 4.79 CAD |
200-Day Moving Average | 5.12 CAD |
GUD.TO Share Statistics
Avg. Volume (3 month) | 132.34K CAD |
Avg. Daily Volume (10-Days) | 74.17K CAD |
Shares Outstanding | 108.84M |
Float | 62.32M |
Short Ratio | 15.2 |
% Held by Insiders | 31.23% |
% Held by Institutions | 13.90% |
Shares Short | 1.96M |
Short % of Float | N/A |
Short % of Shares Outstanding | 1.79% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -4.80% |
Operating Margin (ttm) | -3.55% |
Gross Margin | 46.85% |
EBITDA Margin | 14.92% |
Management Effectiveness
Return on Assets (ttm) | -0.68% |
Return on Equity (ttm) | -1.82% |
Income Statement
Revenue (ttm) | 312.35M CAD |
Revenue Per Share (ttm) | 2.75 CAD |
Quarterly Revenue Growth (yoy) | 29.39% |
Gross Profit (ttm) | 138.06M CAD |
EBITDA | 46.63M CAD |
Net Income Avi to Common (ttm) | -15018000 CAD |
Diluted EPS (ttm) | -0.14 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 177.77M CAD |
Total Cash Per Share (mrq) | 1.63 CAD |
Total Debt (mrq) | 82.64M CAD |
Total Debt/Equity (mrq) | 10.09 CAD |
Current Ratio (mrq) | 2.977 |
Book Value Per Share (mrq) | 7.439 |
Cash Flow Statement
Operating Cash Flow (ttm) | 31.31M CAD |
Levered Free Cash Flow (ttm) | -18222376 CAD |
Profile of Knight Therapeutics Inc.
Country | Canada |
State | QC |
City | Montreal |
Address | 3400 de Maisonneuve Boulevard West |
ZIP | H3Z 3B8 |
Phone | 514-484-4483 |
Website | https://www.gud-knight.com |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | 698 |
Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company also provides Ladevina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.
Q&A For Knight Therapeutics Inc. Stock
What is a current GUD.TO stock price?
Knight Therapeutics Inc. GUD.TO stock price today per share is 5.7 CAD.
How to purchase Knight Therapeutics Inc. stock?
You can buy GUD.TO shares on the Toronto exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Knight Therapeutics Inc.?
The stock symbol or ticker of Knight Therapeutics Inc. is GUD.TO.
Which industry does the Knight Therapeutics Inc. company belong to?
The Knight Therapeutics Inc. industry is Drug Manufacturers-Specialty & Generic.
How many shares does Knight Therapeutics Inc. have in circulation?
The max supply of Knight Therapeutics Inc. shares is 101.17M.
What is Knight Therapeutics Inc. Price to Earnings Ratio (PE Ratio)?
Knight Therapeutics Inc. PE Ratio is now.
What was Knight Therapeutics Inc. earnings per share over the trailing 12 months (TTM)?
Knight Therapeutics Inc. EPS is -0.16 CAD over the trailing 12 months.
Which sector does the Knight Therapeutics Inc. company belong to?
The Knight Therapeutics Inc. sector is Healthcare.
Knight Therapeutics Inc. GUD.TO included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Developed ex US SC NTR G NQDMXUSSCGBPN | 1704.47 GBP 2179.91 USD |
0
|
— — | 1704.47 GBP 2179.91 USD | 1704.47 GBP 2179.91 USD | — - | — — |
- {{ link.label }} {{link}}